| Symbol | RMTI |
|---|---|
| Name | ROCKWELL MEDICAL, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 30142 S. WIXOM ROAD,SUITE 501, WIXOM, Michigan, 48393, United States |
| Telephone | +1 248 960-9009 |
| Fax | — |
| — | |
| Website | https://www.rockwellmed.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001041024 |
| Description | Rockwell Medical Inc is a US-based fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease with its products and services for the treatment of iron deficiency, and hemodialysis. The companys drug products are Triferic. Triferic is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. The company operates in one segment of the hemodialysis market which involves the exports, manufacture, sale, and distribution of hemodialysis products. Key revenue is generated from the United States. Additional info from NASDAQ: |
(30% Negative) ROCKWELL MEDICAL, INC. (RMTI) Reports Q3 2026 Financial Results
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreRockwell Medical to Release Second Quarter 2026 Results on Thursday, August 13, 2026
Read more